News Archive of FierceBiotech

FierceBiotech Radio on pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars02-11-16
Pursuing new deals to grow the pipeline, Szela axes staffers in Aegerion reorg02-11-16
4D pharma buys Tucana to add diagnostic capabilities to microbiome R&D toolkit02-11-16
AveXis and Proteostasis survive the market storm, IPOs raise $145M for R&D02-11-16
Intercept books a date with the FDA as buyout rumors simmer02-11-16
JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials02-11-16
AstraZeneca, Innate Pharma wrap up rollout of first wave of checkpoint inhibitor trials02-11-16
Heptares plans Alzheimer's PhII; AstraZeneca ends I-O trial rollout; 4D buys microbiome firm02-11-16
After 2nd positive PhIII, AbbVie points endometriosis drug elagolix to a 2017 NDA02-11-16
Shire's Ornskov signals a pause in dealmaking after a $50B buyout streak02-11-16
Drew Fromkin tapped to lead Langer's Blend Therapeutics04-17-15
Sanofi and Innate Pharma team up on anti-cancer ADCs04-17-15
Takeda inks a $270M stem cell deal with Kyoto University04-17-15
The FDA calls on Genervon to release data from controversial ALS study04-17-15
AstraZeneca's '$3B' lung cancer drug impresses in a Phase II race with Clovis04-17-15
Athersys tanks as its stem cell therapy flunks a Phase II stroke trial04-17-15
Biotech venture investing continues to sizzle in a big, $1.7B Q104-17-15
Atlas Venture unveils a $280M pure play biotech startup fund04-17-15
Israel awaits $250M fund, ThromboGenics spins out oncology asset, MolMed licenses CAR-T04-16-15
Medicines Co.'s cangrelor finally lines up for FDA approval04-16-15
MolMed picks up CAR-T asset from hot Italian research institute04-16-15
Actelion launches Phase III MS test for ponesimod04-16-15
Galapagos rolls the dice on a $150M IPO, gambling on rheumatoid arthritis drug04-16-15
Buzz: OrbiMed mulls $250M Israeli investment fund04-16-15
Targacept tanks (again) after its last surviving drug program flops 04-16-15
Mystery suitor nears $150M deal to access Intec's 'accordion pill'04-16-15
Pharmalink wraps up PhIIb trial early after interim efficacy data impresses04-16-15
Jeremy Levin's back, building a rare-disease biotech with failed drugs04-16-15
ThromboGenics spins out Roche-rejected cancer drug04-16-15
The flimsy case for a miracle ALS drug collapses under expert scrutiny04-15-15
Amgen wins a much-needed FDA OK for heart drug ivabradine04-15-15
Biogen's novel MS drug shows promise of repairing nerve tissue04-15-15
Pfizer's palbociclib impresses in PhIII breast cancer study04-15-15
Bayer pours $100M into Bay Area R&D with eyes on hemophilia04-15-15
Aduro pulls off a $119M IPO to fund its immuno-oncology pipeline04-15-15
Dominant VC NEA gathers $3B, preps for another wave of biotech rounds04-15-15
Galapagos' closely-watched rheumatoid arthritis drug filgotinib scores in PhIIb04-14-15
Argos gets a $40M China deal for AGS-00304-14-15
New data on GW Pharma's cannabis-based epilepsy drug stokes hopes of success04-14-15
AstraZeneca taps PatientsLikeMe's network for drug R&D insights04-14-15
Merck R&D chief Perlmutter gets a big jump in compensation04-14-15
Incyte is opening an R&D command center in Geneva04-14-15
Bayer hits the gas on its top cancer prospect with Phase III in sight04-14-15
Roche hustles its PD-L1 'breakthrough' star into 11 late-stage trials04-14-15
Roche snags a genomics startup with an eye on cancer R&D04-13-15
After PhIII odyssey, the FDA finally gives Medicines Co. a thumbs-up for cangrelor04-13-15
Drew Fromkin takes the helm at Langer's Blend Therapeutics04-13-15
FDA clears the way for Arrowhead's hep B treatment, with a caveat04-13-15
Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact04-13-15
Big Pharma partner: Check. Crossover round: Check. Hot tech: Check. IPO? 04-13-15
Virtual biotechs a hit with investors and, increasingly, buyers04-10-15
Safety scare with AstraZeneca's diabetes drug could shake up the DPP-4 field04-10-15
Kathrin Jansen to head Pfizer vaccines R&D04-10-15
Tekmira gets the FDA's OK to resume its Ebola study04-10-15
Carbylan pulls off a $65M IPO on its second go-round04-10-15
Struggling Eisai will slash 450 jobs as sales revenue slides04-09-15
Woodford: It's a bubble, Pfizer-backed IO player plans IPO, UniQure cashes in on Bristol deal04-09-15
Shire's billion-dollar eye drug gets in line for a speedy FDA review04-09-15
Cellectis opens new R&D center in New York; Inovio wins $45M Ebola contract; 04-09-15
DBV snags a 'breakthrough' tag for its peanut allergy drug04-09-15
Fast-growing Juno inks lease on a new HQ04-09-15
Prothena files for follow-on offering to build $400M R&D war chest04-09-15
Edge Therapeutics hauls in $72.5M for brain injury R&D04-09-15
Pfizer dumps a hemophilia pact with Catalyst, threatening its Targacept merger04-09-15
Woodford boosts biotech fund max to $1.2B as investors crowd in04-09-15
One of Shire's top blockbuster drug prospects flops in a key PhII study04-09-15
Big Pharma-backed Dutch immuno-oncology player eyes ?100M Nasdaq IPO04-09-15
UniQure plans $100M follow-on offering in afterglow of big-ticket Bristol deal04-08-15
Portola says it's ready to file 'breakthrough' anticoagulant antidote04-08-15
Cardio3 to become Celyad as pivot from CV to CAR-T continues04-08-15
Rhythm rolls into Phase IIb with an Actavis buyout in the balance04-08-15
FDA accepts Novo Nordisk's request for a re-do on once-rejected insulin04-08-15
Woodford to U.S.: You're in a bubble. We're not04-08-15
Merck (sort of) wins back 'breakthrough' boasting rights on hep C04-08-15
Alzheimer's startup Alzheon bags $10M and beats a path to Phase III04-08-15
Regulus surges after AstraZeneca snags rights to NASH drug04-07-15
Clovis one-ups AstraZeneca with a 'breakthrough' tag for its cancer drug04-07-15
CRISPR-Cas9 pioneer starts recruiting R&D group in Cambridge hub04-07-15
Nabriva preps for PhIII antibiotic trial with a $120M VC commitment04-07-15
Fresh off a $76M raise, aTyr pilots an $86M IPO04-07-15
Plotting a course for True North, biotech CEO steps up with a $35M round04-07-15
Merck wagers $434M on Arvinas and its protein-disposal system04-07-15
High-flying immuno-oncology player Adaptimmune pitches $150M IPO 04-06-15
Ocular Therapeutix plunges as eye treatment blurs the line in PhIII 04-06-15
Flexus founders regroup after $1.25B Bristol-Myers deal04-06-15
Woodford pours another $40M into Northwest Bio and its brain cancer vaccine04-06-15
Alkermes heads to Phase III with a schizophrenia drug designed to spare the waistline04-06-15
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet04-06-15
Juno and Novartis settle CAR-T patent fight with little fanfare04-06-15
Bristol-Myers bets big on gene therapy with a $1B uniQure deal04-06-15
GlaxoSmithKline to create new vaccines hub, uprooting R&D groups in Cambridge, Philly04-02-15
23andMe poaches another Genentech vet as it delves into biotech04-02-15
AstraZeneca razes R&D facilities in Delaware04-02-15
Sarepta CEO Chris Garabedian resigns04-01-15
Ipsen barrels into Boston with a new R&D hub and a Harvard pact04-02-15
Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou04-02-15
Sanofi adds a $120M computational drug design deal with Schrödinger04-02-15
Parisian IPO boomlet marches on, Cardio3 rides CAR-T to Wall Street, PhII flop smacks Can-Fite04-02-15
Fast-track approvals gain traction in Europe as EMA, U.K. schemes take off04-02-15
Index Ventures banks 650M euros for its new tech fund 04-02-15
PureTech's heavyweight contender Gelesis swings for a $60M IPO04-02-15
Yale team says failed AstraZeneca drug shows promise in Alzheimer's04-01-15
Calico sheds light on its R&D mission with UCSF partnership04-01-15
Cardio3 pitches its stem cell, CAR-T pipeline to U.S. investors04-01-15
Prepping for a Duchenne study, Catabasis banks $12.4M in new fundraising04-01-15
VC heavyweights back a $150M NYC biotech fund with Lilly and Celgene in tow04-01-15
Roche CEO Schwan flags more biopharma partnering ahead04-01-15
PledPharma jumps 20% on PhII chemotherapy-induced nerve damage data04-01-15
FierceBiotech Radio with J&J Innovation's Ken Drazan04-01-15
A big $76M round, undisclosed investors; is an IPO looming for aTyr?04-01-15
Sarepta's embattled CEO steps down as DMD drug heads to the FDA04-01-15
A massive M&A day stokes hopes for more biotech buyouts, but where's the bottom?03-31-15
Parisian IPO boomlet continues with Sensorion setting terms03-31-15
Chi-Med's fruquintinib meets colorectal cancer PhII primary endpoint03-31-15
On the road to Cambridge, migraine drug biotech CoLucid files for an $86M IPO03-31-15
GlaxoSmithKline leads a $21M round for PhII kidney drug developer Thrasos03-31-15
Can-Fite sinks 60% to all-time low after PhII/III flop03-31-15
Bayer taps the Broad Institute for cardio R&D03-31-15
Merck ties up with tiny Syndax on a 'breakthrough' cancer combo03-31-15
Aegerion reaches a cease-fire with its activist agitators03-31-15
Fujifilm bags stem cell pioneer Cellular Dynamics in $307M buyout03-31-15
Houston-based gene therapy outfit files for $70M IPO03-30-15
BioDelivery tanks as its pain gel comes up short in Phase III03-30-15
Skincare startup bags $50M to get its acne drug into Phase III03-30-15
UPDATED: Merck KGaA forges a $941M CAR-T development deal with Intrexon03-30-15
Novartis bulks up in immuno-oncology with a $750M Aduro deal03-30-15
Teva scoops up Auspex and NDA-ready CNS drug in $3.2B buyout03-30-15
Lilly and Boehringer roll toward EU approval with diabetes combo03-27-15
Former Teva CEO Levin returns to biopharma as chairman of upstart Ovid Therapeutics03-27-15
Shire, BioMarin and the snowball effect of buyout rumors03-27-15
Novo Nordisk speeds back to the FDA with its once-rejected insulin03-27-15
MorphoSys tanks after Celgene walks away from $818M pact03-27-15
Ohr Pharma's eye drop fails a Phase II AMD trial03-27-15
Billionaires drive Malin to ?330M IPO, Push for EU JOBS Act, RNAi stock jumps on PhIIa data03-26-15
Genfit's NASH drug flunks Phase II, but management sees a silver lining03-26-15
After Salix's $10B deal, is Synergy Pharma on the block?03-26-15
Conatus heralds success for its NASH drug and plots Phase III03-26-15
Big Pharma joins the U.K.'s genomics project with eyes on drug discovery03-26-15
FierceBiotech Radio on the biotech bubble and #FierceMadness03-26-15
Finance giants lobby for JOBS-style reforms to EU IPO laws03-26-15
Amgen uncovers trove of gene knockouts in 'molecular national selfie'03-26-15
Flagship banks $537M to back the next batch of biotechs03-26-15
Cellectis pulls off a $228M IPO to bankroll its CAR-T ambitions03-25-15
Novartis' psoriasis rivals tout impressive data with next-gen treatments03-25-15
Emergent Bio bags FDA approval for another anthrax treatment03-25-15
AstraZeneca buys into Harvard's stem cell tech for diabetes R&D03-25-15
GlaxoSmithKline mounts an open casting call for R&D starlets03-25-15
Novartis chief: Sometimes you have to kill your R&D darlings03-25-15
Cellectis upscales IPO toward $200M as CAR-T fever continues03-25-15
New Alzheimer's study escalates the old amyloid-tau debate03-24-15
Blueprint plots a $100M IPO for its precision medicine platform03-24-15
VC vets break new ground with $42M Polish life science fund03-24-15
Google's Calico widens its R&D net with QB3 partnership03-24-15
Bristol, Sanofi and Novartis lead pack in big year for blockbusters03-24-15
Bristol-Myers picks up an autoimmune project as Novo quits the field03-24-15
FierceBiotech Radio and EP Vantage on biotech's big 201403-24-15
Diabetes startup rakes in $44M and teams up with Novartis on cell therapy03-24-15
Video: Is this a biotech bubble?03-23-15
Investors hype Silence Therapeutics after cancer drug shows promise in PhIIa03-23-15
GlaxoSmithKline taps Cold Spring Harbor for diabetes R&D03-23-15
Novartis, Lilly lead a $44M round for rare disease biotech Aeglea03-23-15
In a squeaker, FierceBiotech readers warn of a biotech bubble03-23-15
Seventure adds ?25M to microbiome investment fund03-23-15
Billionaires line up to back Malin's ?330M IPO03-23-15
Biogen's future: bigger bets on CNS, smaller name03-23-15
ImmunoGen strikes $440M ADC deal with Takeda03-23-15
FDA removes the brakes on Pfizer and Lilly's pain drug03-23-15
MEI's second go at cancer R&D flunks a Phase II MDS trial03-23-15
Tal Zaks lands at Moderna as CMO03-20-15
AstraZeneca's rosy pipeline promise runs into harsh realities in oncology03-20-15
Amgen fails to block Novartis' Neupogen biosimilar03-20-15
Sanofi finally unloads an embattled R&D site in $270M Evotec deal03-20-15
Lilly inks a $456M oncology deal with China's Innovent03-20-15
Biogen's Alzheimer's drug impresses in early study with Phase III on the way03-20-15
Prothena rockets up with early data on a Roche-partnered Parkinson's drug03-20-15
Woodford backs Malin's ?325M IPO, U.K. rejigs VC trust rules, Genmab shuffles antibody assets03-19-15
Biotech spared in U.K. rejig of VC trusts03-19-15
Analysts spread the love as Biogen Idec excites on MS, Alzheimer's03-19-15
Lilly inks a $690M deal to get its hands on an autoimmune drug03-19-15
What, Juno worried about its cash burn? Not likely03-19-15
Genmab buys iDD antibody assets, drops ADC co-development rights03-19-15
Google's mystery biotech Calico partners with the Broad on aging-related drugs03-19-15
Crohn's expert flags blockbuster potential--and frets--of Celgene's mongersen03-19-15
J&J stays mum about cash, but biotech buyout is a landmark win for Index fund03-18-15
Sirtex gets hammered on failed cancer study03-18-15
Retrophin bags rare disease approval, FDA voucher in $75M deal03-18-15
AstraZeneca's $1.2B COPD drug comes through in Phase III03-18-15
Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears03-18-15
Nordic Nanovector upscales IPO as demand tops expectations03-18-15
Pfizer joins a powerhouse syndicate backing $43M round for Nimbus03-18-15
Nektar looks for the positive in a failed PhIII breast cancer study03-17-15
Struggling GlaxoSmithKline warns of 150 R&D job cuts in Philadelphia 03-17-15
Woodford backs Malin to move ex-Elan execs toward ?325M IPO goal03-17-15
What drives Peter Thiel's biotech investment strategy? Trends are 'bad'03-17-15
Soon-Shiong's NantWorks deepens its immuno-oncology ties with Sorrento03-17-15
Galapagos registers another setback as J&J dumps anti-inflammatory pact03-17-15
Esperion's potential PCSK9 spoiler scores more positive data03-17-15
CAR-T player Kite Pharma buys its way into Europe and pads its anticancer arsenal03-17-15
GlaxoSmithKline and J&J back a $100M new Alzheimer's R&D project03-17-15
Department reorganizations at Biogen Idec raise fears of future cuts03-16-15
Chiasma taps a new CEO as it rolls toward an FDA filing03-16-15
Pulmatrix backs its way onto Wall Street with merger deal03-16-15
R&D exec Tal Zaks leaps from flagging Sanofi to fast-growing Moderna03-16-15
Cidara Therapeutics makes a quick leap into the growing Q1 IPO queue03-16-15
Amgen scores a victory for PCSK9, halving cardio risks after one year03-15-15
Merck can't get the sugammadex curse lifted, faces 3rd FDA rejection03-14-15
XBiotech lines up for a $76M IPO to fund its antibody R&D03-13-15
Baxter's latest hemophilia drug comes through in Phase III03-13-15
With drug discovery ambitions, 23andMe recruits Genentech vet Scheller03-13-15
Bristol-Myers heads back to the FDA with its long-delayed hep C drug03-13-15
Biogen Idec trims R&D staff, looks for new talent in chemistry, neurology 03-12-15
Sanofi backs immunotherapy hub, U.K. mulls its own 'breakthrough,' Allergy player banks £20M03-12-15
Third Rock's faded Ember gets resuscitated in merger deal03-12-15
Allergy biotech hauls in $80M for its oral immunotherapy03-12-15
Sustainable bull market or biotech bubble? What do you think?03-12-15
U.K. looks to FDA 'breakthrough' status for inspiration in regulatory revamp03-12-15
Neuralstem tanks on cloudy results for its ALS treatment03-12-15
Epizyme retrieves global rights to cancer drug in $110M deal03-12-15
23andMe dives into biotech with Genentech R&D star Richard Scheller on board03-12-15
J&J partner Aduro rides the immuno-oncology wave with $86M IPO03-12-15
AstraZeneca gambles on a $40M round for diabetes/cardio biotech PhaseBio03-12-15
Kura sheds stealth mode with $60M for PhII cancer drug licensed from J&J 03-12-15
Alcobra misses efficacy endpoint in ADHD trial03-12-15
Allergy Therapeutics raises £20M to bounce back from 5-year clinical hold03-12-15
Wilex hands back some cancer drugs as it circles the biotech drain05-21-14
Shire heads to the FDA with its dry eye drug despite a so-so PhIII05-21-14
AstraZeneca partner Ardelyx pitches $69M IPO05-21-14
Swelling ranks of AstraZeneca's dissident shareholders press for a Pfizer deal05-21-14
Gene therapy upstart bags a $22M A round for neurodegenerative work05-21-14
Takeda overcomes safety questions, wins FDA OK for IBD drug vedolizumab05-20-14
SEC cries insider trading in GTx's halted cancer trial05-20-14
R.I.P.: Merck and Endocyte yank vintafolide app 05-20-14
Clovis bags 'breakthrough' tag for its cancer drug as ASCO's spotlight awaits05-20-14
Angry AstraZeneca investors may hold the only key to a Pfizer deal05-20-14
Pioneering CAR-T biotech upstart plans to leapfrog into a $115M IPO05-20-14
Pharma's checkbook keeps M&A flowing as biotech stays lukewarm05-20-14
Novartis hands Ophthotech a $1B deal for heavyweight wet AMD contender05-19-14
KKR steps in to back $55M C round for biosimilars developer Coherus05-19-14
State legislatures jump into the thorny compassionate-use debate05-19-14
Why did Pfizer's big fiesta for palbociclib fizzle?05-19-14
Another animal health biotech plots an IPO05-19-14
Bristol-Myers nabs another 'breakthrough' cancer drug title05-19-14
Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data05-19-14
Pfizer hikes bid for AstraZeneca to $117B, but swears off hostile maneuver05-18-14
Pfizer's vows fall on deaf ears in Cambridge05-16-14
Kamada tanks as its lead drug can't top placebo05-16-14
Forest CEO Saunders to lead combined company after Actavis buyout05-16-14
Gelesis brings in $12M to advance its obesity pill05-16-14
Gates, Wellcome bet $40M on Kymab's antibody tech05-16-14
Proteon banks $45M for vascular drug with Novartis in the rearview05-16-14
FDA rejects Novartis' 'breakthrough' cardio drug serelaxin05-16-14
J&J and Pfizer pursue contrasting strategies, AZ backs biotech fund, Bayer opens Berlin incubator05-16-14
Novartis-backed Sorbent grabs first tranche in $15M heart therapy round05-15-14
Bluebird bio buoyed by news of looming trial data05-15-14
ZS Pharma looks to $86M IPO to fund PhIII hyperkalemia studies05-15-14
AstraZeneca: Coming up from behind--fast--with top cancer programs05-15-14
Bristol-Myers Squibb: It's all about the "breakthrough" drug nivolumab now05-15-14
What we learned from the big ASCO cancer drug data dump05-15-14
Novartis, Servier team up on tumor-killing drug development05-14-14
Don't look for industry insiders to back another Pfizer megamerger05-14-14
J&J scouts for 50 Bay biotechs with new Janssen incubator05-14-14
PhIII eye drug failure? Not at all, says an optimistic Gene Signal 05-14-14
FDA breaks silence on biosimilars with long-awaited proposal05-14-14
Isis heralds positive PhII diabetes results from leading antisense drug05-14-14
AstraZeneca adds an immuno-oncology collaboration for its pipeline star05-14-14
AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline05-13-14
Valeant readies a sweetened bid for Allergan05-13-14
Marinus braves a cooling biotech IPO market with a $63M pitch05-13-14
Pfizer's quest for AstraZeneca becomes political theater as MPs probe $106B offer05-13-14
Startup brings together some of Boston's top biotech brains and bucks 05-13-14
GlaxoSmithKline's blockbuster dreams dashed as darapladib goes 0-for-2 in PhIII05-13-14
Chase banks $21M round for Alzheimer's drug research05-12-14
Pfizer makes a case for R&D in AstraZeneca megamerger, but does anyone believe it?05-12-14
Lilly draws flak after touting PhIII diabetes success for Lantus rival05-12-14
Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant05-12-14
Show me the money: Which drugs made the top 10 list on upfront deals?05-12-14
Deal-hungry Shire nabs Lumena for $260M as M&A frenzy intensifies 05-12-14
Amgen, AstraZeneca score a PhIII psoriasis success with brodalumab05-09-14
New immunotherapy uses patient's cells to attack tumors05-09-14
Merck KGaA bets on biosimilars with an eye on M&A05-09-14
Bristol-Myers' senior VP of global development retires05-09-14
Pfizer cozies up to U.K. scientists amid transatlantic scrutiny05-09-14
Biotech's post-boom swoon mars IPO efforts from Radius, Agile05-09-14
Novartis-backed ImaginAb banks $21M for antibody tech05-09-14
'Biotech savior' sets up £4.5B fund, U.K. polls a hassle for Pfizer, Meda to join M&A frenzy05-08-14
'Biotech savior' sets up £4.5B fund, U.K. polls a hassle for Pfizer, Meda to join M&A frenzy05-08-14
Merck wins FDA approval for a once-vaunted cardio drug05-08-14
AstraZeneca rushes immuno-oncology star into PhIII lung cancer study 05-08-14
AbbVie makes a run at early EU OK for hep C cocktail05-08-14
Does Alder's IPO setback signal that the biotech IPO boom is ending? 05-08-14
Early-stage cancer drug pipeline booms as payers dig in for a fight05-08-14
Lundbeck is buying Chelsea for $658M, with a just-in-case clause05-08-14
Pfizer's megamerger pitch haunted by empty promises of the past 05-08-14
Erectile dysfunction drugs improve blood flow in Duchenne boys05-07-14
Corcept tanks as depression drug comes up short in Phase III05-07-14
Roche and Exelixis tout PhI cancer combo with late-stage data on the way05-07-14
Cytomedix shutters R&D site after PhII failure05-07-14
Waiting for U.S. pols to block the Pfizer-AstraZeneca megamerger? Forget about it05-07-14
Who will buy into AstraZeneca's "$5B" high-risk Alzheimer's drug? 05-07-14
The top R&D spenders in biopharma in 201305-07-14
Marquee VCs back a $37.5M launch round for immune-tolerant drugs05-07-14
Loxo lands $24M venture round and a CSO for cancer drug research 05-06-14
Naurex picks up $25M to get its depression drugs through PhII05-06-14
Merck's hot immuno-oncology prospect MK-3475 grabs clear lead in blockbuster race05-06-14
Merck pays $1B to buy into Bayer's cardio future05-06-14
AstraZeneca promises investors a magnificent future--without Pfizer05-06-14
AstraZeneca wins FDA OK for another fish-oil heart pill, enters crowded market 05-06-14
Aeterna announces plans for new commercial hub05-05-14
Novartis' long-acting Signifor passes PhIII test for acromegaly05-05-14
Global R&D centers brace for new blows as Pfizer circles AstraZeneca05-05-14
Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO05-05-14
Regeneron jumps into next-gen gene therapy tech with $640M eye drug deal05-05-14
AstraZeneca's R&D image problem haunts its fight against Pfizer 05-05-14
GlaxoSmithKline picks up FDA approval for its latest COPD contender05-02-14
Acorda's seizure spray gets the FDA blow-off05-02-14
Endo appoints former Bausch + Lomb exec to head corporate strategy05-02-14
Merck halts study of the billion-dollar cancer drug vintafolide05-02-14
FDA rejects The Medicines Co.'s clot-buster, sending cangrelor back to the clinic05-02-14
Britain fearful of Pfizer future, UCB on the hunt for antibody partners, Novartis snubs Transgene05-01-14
AstraZeneca dismisses Pfizer's $106B bid, ignores R&D commitment05-02-14
Britain fearful of Pfizer future, UCB on the hunt for antibody partners, Novartis snubs Transgene05-01-14
Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal05-02-14
UPDATED: Ex-champ Vertex dumps hep C, but shares spike on positive CF results05-01-14
Enterome raises $11.5M for gut microbiome R&D05-01-14
Amid Zohydro controversy, Teva, Purdue and Pfizer race ahead with new pain drugs05-01-14
VC Lightstone lands $172M fund with an eye on biotech startups05-01-14
Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout05-01-14
Can anything prevent Pfizer's megamerger with AstraZeneca?05-01-14
Merrimack heads to the FDA after scoring positive PhIII for pancreatic cancer 05-01-14
Biopsy snafu torpedoes PhII prostate cancer data for Nymox04-30-14
GlaxoSmithKline ups odds on heart drug hopeful with a changeup in endpoints 04-30-14
Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada04-30-14
Ex-champ Vertex calls it quits on hep C, concentrates on CF05-01-14
Enterome raises $11.5M for gut microbiome R&D05-01-14
Amid Zohydro controversy, Teva, Purdue and Pfizer race ahead with new pain drugs05-01-14
VC Lightstone lands $172M fund with an eye on biotech startups05-01-14
Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout05-01-14
Can anything prevent Pfizer's megamerger with AstraZeneca?05-01-14
Merrimack heads to the FDA after scoring positive PhIII for pancreatic cancer 05-01-14
Biopsy snafu torpedoes PhII prostate cancer data for Nymox04-30-14
GlaxoSmithKline ups odds on heart drug hopeful with a changeup in endpoints 04-30-14
Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada04-30-14
Ex-champ Vertex calls it quits on hep C, concentrates on CF05-01-14
Enterome raises $11.5M for gut microbiome R&D05-01-14
Amid Zohydro controversy, Teva, Purdue and Pfizer race ahead with new pain drugs05-01-14
VC Lightstone lands $172M with an eye on biotech startups05-01-14
Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout05-01-14
Can anything prevent Pfizer's megamerger with AstraZeneca?05-01-14
Merrimack heads to the FDA after scoring positive PhIII for pancreatic cancer 05-01-14
Biopsy snafu torpedoes PhII prostate cancer data for Nymox04-30-14
GlaxoSmithKline ups odds on heart drug hopeful with a changeup in endpoints 04-30-14
Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada04-30-14
Regeneron R&D chief's compensation shrinks, but still tops the chart04-30-14
Otonomy pockets $49M to hit the gas on its ear treatments04-30-14
Novartis grabs early FDA approval of lung cancer drug Zykadia04-29-14
Transgene takes a hit as Novartis shreds $800M option deal04-29-14
CytoKinetics' ALS drug also misses string of secondary endpoints04-29-14
Why would Pfizer want to buy AstraZeneca? It's not R&D04-29-14
Allergan woos J&J, Sanofi while keeping its eyes on Shire, per reports04-29-14
Amicus shares rally as a revised PhIII delivers positive Fabry data04-29-14
Bristol-Myers racing to the FDA with immunotherapy star nivolumab04-29-14
Bristol-Myers targets neurodegenerative diseases in $725M deal to buy iPierian04-29-14
On heels of an IPO, Concert's kidney drug flops in PhII04-28-14
Merck turns to tiny Agenus in hunt for new immunotherapies 04-28-14
Onco-immunotherapy specialist Kite adds $50M in new financing04-28-14
OncoGenex, Teva flag a failed PhIII for prostate cancer drug04-28-14
Forest lands Furiex and expands GI business in $1.5B buyout deal04-28-14
Ignoring harsh lessons, Pfizer prepares to pounce on AstraZeneca04-28-14
Biogen brings Quintiles to the R&D table in 5-year pact04-25-14
Isarna snags another $7.6M to advance its cancer immunotherapy04-25-14
Actavis global R&D president departs to helm Impax Labs04-25-14
Radius dials up a $92M IPO pitch despite tepid market for biotechs04-25-14
Buyout buzz: Allergan made a pass at Shire before Valeant came calling04-25-14
Arch Venture swings for a $250M fund to bet on biotechs04-25-14
Cytokinetics tanks as ALS drug fails a mid-stage study, jeopardizing the program04-25-14
GSK and Novartis reshape EU biotech, Celgene and Hyperion in Euro deals, U.K. cell therapy grows04-25-14
Juno wraps up a $176M A round as it hits the gas on its CAR-T contender04-24-14
Hyperion bets up to $570M on diabetes biotech Andromeda04-24-14
Celgene shells out $710M for a PhIII Crohn's drug04-24-14
J&J snags FDA OK for rare blood disorder drug siltuximab 04-24-14
AstraZeneca continues to chop back, spotlights immuno-oncology PhIII04-24-14
An international biotech tackles CRISPR gene editing tech with $25M bankroll04-24-14
GSK's R&D staff hit with trade rumors spurred by Novartis cancer deal04-23-14
Novartis, GSK deal puts the spotlight on a narrowing R&D focus04-23-14
Spectrum touts PhII cancer data, plans NDA04-23-14
Amgen beats a path to the FDA, looking for an early approval of leukemia drug04-23-14
Kala reels in $22.5M to get its next-gen eye drops into PhIII04-23-14
Shooting for IPO glory, Alder cites trial success with migraine drug 04-23-14
Allergan fashions a poison pill as raiders at Valeant promise to gut R&D04-23-14
Epizyme jumps on $4M payday04-22-14
AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck04-22-14
ProNAi nabs $59.5M round to back PhII lymphoma drug04-22-14
GSK punts much of its cancer R&D work in Big Pharma swap and shop04-22-14
FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer04-21-14
Activist investor teams with Valeant on quest to acquire Allergan04-21-14
Aastrom surges after acquiring Sanofi's cell therapies 04-21-14
Former Creighton professor named chief medical officer at 23andMe 04-21-14
Sarepta rockets up after mapping a shortcut to the FDA with DMD hopeful eteplirsen04-21-14
Zafgen tees up an $86M IPO for eye-catching obesity drug04-20-14
Report: Pfizer pitches $101B megamerger to struggling AstraZeneca04-20-14
FDA lifts its hold on Juno's cutting-edge cancer drug after deaths trigger delay04-19-14
Biotech VCs wager $1.1B in Q1, starting the year with a flurry of new deals 04-18-14
Nasdaq volatility delays IPO, Almirall pulls drug over price, Topotarget to merge as PDUFA nears04-18-14
Corey Goodman backs $20M A round for heart drug biotech04-17-14
Pfizer, AstraZeneca back a new strategy for cancer drug R&D04-17-14
Vital Therapies banks $54M in a downsized IPO retry04-17-14
GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks04-17-14
Biotech upstart grabs $18M to study a new drug to protect pregnancies04-17-14
Which therapies top Thomson Reuters' list of new drugs to watch this year?04-17-14
Baxter's latest bleeding drug hits the mark in PhIII04-16-14
Column Group nears goal line for $250M biotech venture fund04-16-14
BioAlliance and Topotarget plan to merge, pooling their cancer pipelines04-16-14
Have the biotech bears run out of steam?04-16-14
VCs gamble $96M on rare disease drug, biosimilar play and new drug for AMD04-16-14
Boehringer dogged by doubts as it touts a growing PhIII pipeline04-16-14
GlaxoSmithKline wins an FDA nod for its new diabetes drug04-15-14
Angion swings for a $36M IPO as biotech's bear turn drags on04-15-14
Little Lexicon posts positive diabetes data as rival pharma giants race ahead04-15-14
Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy04-15-14
Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary04-15-14
Merck bags FDA approval for its grass pollen pill04-14-14
ThromboGenics is picking between billion-dollar bids, report says04-14-14
NeoStem strikes deal to acquire California Stem Cell04-14-14
BREAKING: Novartis slams the brakes on RNAi development efforts04-14-14
J&J axes a late-stage Botox rival, chopping project staffers04-14-14
J&J teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort 04-14-14
Cytos hits the self-destruct button as PhIIb asthma study bombs04-14-14
Intercept grabs the spotlight at EASL, builds case for lead drug OCA04-12-14
National Cancer Institute investigating trial outliers to resurrect 'failed' drugs04-11-14
Biotech stocks tumble on phantom terror as analysts struggle to explain04-11-14
Chimerix CEO Moch steps down after compassionate-use controversy04-11-14
AbbVie angles for hep C spotlight as Merck shoulders to the front04-11-14
Impax gives it another go with a once-rejected Parkinson's drug04-11-14
Bayer backs VC fund, FBI calls Russian VCs thieves, Oryzon and Serendex plan IPOs04-11-14
VCs gamble $45M on PhII pain drug, new U.S. base for Spinifex04-09-14
Three IPO hopefuls look to squeeze out $144M as biotech gets bearish04-10-14
Cerulean stumbles with IPO as investors fret over biotech stocks 04-10-14
Biogen's hemophilia hopeful scores a PhIII win as FDA awaits04-10-14
Bristol-Myers jockeys for promising position in hep C drug race04-10-14
Celladon's heart drug grabs 'breakthrough' status at FDA04-10-14
Soon after media storm fades, Chimerix CEO Moch is out the door04-10-14
Watch out Gilead, Merck is mounting a hep C combo comeback04-10-14
FDA drops a hold on Halozyme study04-09-14
'Special K' once again wows investigators in small depression study 04-09-14
Novartis, NEA join $188M gamble on China biotech fund 04-09-14
After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky04-09-14
GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance 04-09-14
Meet Spero, a biotech hopeful with Roche's blessing and a novel antibiotic04-09-14
Low-profile Alios gets a roster of Big Pharma funds to back anti-RSV therapy04-08-14
Lilly preps a PhIII study as breast cancer drug race heats up 04-08-14
TetraLogic bags lymphoma therapy in $13M buyout04-08-14
Versant gambles $12M on Swiss PI3K/mTOR cancer drug upstart 04-08-14
Deerfield eyeing new biotech investments after launching $1.6B fund04-08-14
Alkermes hits PhIII goal line with 'blockbuster' long-acting schizophrenia drug04-08-14
Puma surges as neratinib beats Herceptin in head-to-head breast cancer study04-07-14
Little Deciphera raises its cancer R&D flag in Boston's bustling biotech hub04-07-14
Agios shares spike on enthusiastic response to small, early-stage leukemia study04-07-14
Biotech's breathless quarter of IPOs brings in $2.1B for R&D04-07-14
Roche's pRED jumps into epigenetics with $521M-plus cancer drug deal04-07-14
Sanofi decides to take a second shot on Lemtrada app04-07-14
Pfizer's flagship palbociclib stymies cancer progression, but falls short on survival04-06-14
Memorial Sloan-Kettering hits the brakes on engineered T cell cancer study04-06-14
All eyes on Pfizer as palbociclib prepares to take the stage04-04-14
Merck and Ferring team up on anti-bleeding drug for the developing world04-04-14
AbbVie gets out of the way as the EU prepares for trial transparency04-04-14
Novartis gets new head of Japanese business amid misconduct investigations04-04-14
Amgen's viral cancer vaccine misses its survival goal in melanoma PhIII04-04-14
GTx's CEO finds the door as the company moves on from a PhIII failure04-04-14
Halozyme tanks after another mid-stage setback dings its cancer drug04-04-14
InDex mulls Swedish IPO, Circassia backer posts profit jump, U.K. targets bio investment04-04-14
Sanofi sets sights on Africa with an eye on M&A04-03-14
Pharma giants jostle for the cancer R&D spotlight at AACR04-03-14
Corium pulls off a $52M IPO to fund its needle-free pipeline04-03-14
Celgene pays VCs $47M to up its stake in Acceleron's pipeline 04-03-14
Novartis-backed Neurovance bags $6.3M to focus on ADHD04-03-14
Party drug turned 'miracle' cure for depression spurs hype and stubborn hope 04-03-14
Lumena swings for a $75M IPO to bear down on liver diseases04-03-14
Battered Amarin finally lands a partner for Vascepa04-02-14
Baxter snaps up its hemophilia partner on the verge of a biotech breakup04-02-14
Analysts, experts are dazzled by the blockbuster potential of Novartis' LCZ696 04-02-14
Stallergenes beats Merck to market as FDA OKs its allergy pill04-02-14
GlaxoSmithKline shutters lung cancer vaccine study on latest MAGE-A3 setback04-02-14
FDA panel backs MannKind's inhaled insulin as commercial questions linger04-01-14
Danish trial results show stem cells improve failing hearts04-01-14
Merck KGaA teams up with Pfizer to spotlight new lupus therapies04-01-14
Foresite banks $300M to bet on late-stage biotechs04-01-14
Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy04-01-14
Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option 04-01-14
Cubist's superbug drug clears FDA panel, lines up for Pfizer showdown03-31-14
AstraZeneca cozies up to MRC scientists amid an R&D rethink03-31-14
FDA lifts a partial hold on Curis cancer drug03-31-14
Glaxo scraps the ovarian cancer app for Votrient03-31-14
Shares of Prana collapse after long-shot Alzheimer's study flops03-31-14
Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol03-31-14
On the ropes, Novartis' cardiology team declares a blockbuster PhIII knockout 03-31-14
GlaxoSmithKline's darapladib team finds hope in a PhIII bomb 03-30-14
Amgen's PCSK9 drug slashes 'bad' cholesterol in PhIII, stoking blockbuster hopes03-30-14
Biogen wins FDA OK for long-acting hemophilia drug Alprolix03-28-14
AstraZeneca looks to China for kidney disease R&D03-28-14
Ebola still a tough target due to Big Pharma disinterest and few outbreaks03-28-14